Comorbidities in multiple myeloma and implications on survival: A population-based study

Area of Science:

• Hematology
• Oncology
• Epidemiology

Background:

• Multiple myeloma patients frequently present with comorbidities.
• Comorbidities can complicate treatment and affect patient outcomes.

Purpose of the Study:

• To determine the prevalence of comorbidities in multiple myeloma patients.
• To assess the impact of comorbidities on survival in multiple myeloma.

Main Methods:

• Retrospective analysis of 13,656 Swedish patients diagnosed with multiple myeloma between 1990-2013.
• Inclusion of all patient diagnoses from 1985 onwards to capture comorbidity history.
• Statistical analysis of comorbidity prevalence and hazard ratios for mortality.

Main Results:

• 54% of multiple myeloma patients had at least one comorbidity at diagnosis.
• Increased risk of death observed with increasing number of comorbidities (HR 1.19 for one, 1.38 for two, 1.72 for three or more).
• Specific comorbidities like cancer history, heart failure, diabetes, and chronic kidney disease were associated with increased mortality risk.

Conclusions:

• Comorbidities are highly prevalent in multiple myeloma at diagnosis.
• The number of comorbidities is inversely related to patient survival.
• Integrating comorbidity assessment into clinical management is crucial for optimizing multiple myeloma treatment strategies.